Literature DB >> 25236341

Permeability of PEGylated immunoarsonoliposomes through in vitro blood brain barrier-medulloblastoma co-culture models for brain tumor therapy.

Abdulghani Al-Shehri1, Marco E Favretto, Panayiotis V Ioannou, Ignacio A Romero, Pierre-Olivier Couraud, Babette Barbash Weksler, Terry L Parker, Paraskevi Kallinteri.   

Abstract

PURPOSE: Owing to restricted access of pharmacological agents into the brain due to blood brain barrier (BBB) there is a need: 1. to develop a more representative 3-D-co-culture model of tumor-BBB interaction to investigate drug and nanoparticle transport into the brain for diagnostic and therapeutic evaluation. 2. to address the lack of new alternative methods to animal testing according to replacement-reduction-refinement principles. In this work, in vitro BBB-medulloblastoma 3-D-co-culture models were established using immortalized human primary brain endothelial cells (hCMEC/D3).
METHODS: hCMEC/D3 cells were cultured in presence and in absence of two human medulloblastoma cell lines on Transwell membranes. In vitro models were characterized for BBB formation, zonula occludens-1 expression and permeability to dextran. Transferrin receptors (Tfr) expressed on hCMEC/D3 were exploited to facilitate arsonoliposome (ARL) permeability through the BBB to the tumor by covalently attaching an antibody specific to human Tfr. The effect of anticancer ARLs on hCMEC/D3 was assessed.
RESULTS: In vitro BBB and BBB-tumor co-culture models were established successfully. BBB permeability was affected by the presence of tumor aggregates as suggested by increased permeability of ARLs. There was a 6-fold and 8-fold increase in anti-Tfr-ARL uptake into VC312R and BBB-DAOY co-culture models, respectively, compared to plain ARLs.
CONCLUSION: The three-dimensional models might be appropriate models to study the transport of various drugs and nanocarriers (liposomes and immunoarsonoliposomes) through the healthy and diseased BBB. The immunoarsonoliposomes can be potentially used as anticancer agents due to good tolerance of the in vitro BBB model to their toxic effect.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25236341     DOI: 10.1007/s11095-014-1519-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

1.  In vitro model for evaluating drug transport across the blood-brain barrier.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Drug delivery and in vitro models of the blood-brain barrier.

Authors:  Luca Cucullo; Barbara Aumayr; Edward Rapp; Damir Janigro
Journal:  Curr Opin Drug Discov Devel       Date:  2005-01

3.  NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics.

Authors:  Nahal Ketabi-Kiyanvash; Christel Herold-Mende; Farzaneh Kashfi; Sandra Caldeira; Massimo Tommasino; Walter E Haefeli; Johanna Weiss
Journal:  Cell Tissue Res       Date:  2006-12-19       Impact factor: 5.249

4.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

5.  Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT.

Authors:  A Régina; I A Romero; J Greenwood; P Adamson; J M Bourre; P O Couraud; F Roux
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

Review 6.  Barriers to carrier mediated drug and gene delivery to brain tumors.

Authors:  Grace H Huynh; Dennis F Deen; Francis C Szoka
Journal:  J Control Release       Date:  2005-11-28       Impact factor: 9.776

7.  Effects of hypoxia on endothelial/pericytic co-culture model of the blood-brain barrier.

Authors:  Kentaro Hayashi; Shinobu Nakao; Ryota Nakaoke; Shinsuke Nakagawa; Naoki Kitagawa; Masami Niwa
Journal:  Regul Pept       Date:  2004-12-15

8.  Zero-length crosslinking procedure with the use of active esters.

Authors:  Z Grabarek; J Gergely
Journal:  Anal Biochem       Date:  1990-02-15       Impact factor: 3.365

Review 9.  Drug targeting to the brain.

Authors:  William M Pardridge
Journal:  Pharm Res       Date:  2007-06-07       Impact factor: 4.200

10.  Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions.

Authors:  M Furuse; M Itoh; T Hirase; A Nagafuchi; S Yonemura; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  4 in total

Review 1.  Human mini-brain models.

Authors:  Hsih-Yin Tan; Hansang Cho; Luke P Lee
Journal:  Nat Biomed Eng       Date:  2020-12-14       Impact factor: 25.671

2.  Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.

Authors:  Waranyoo Phoolcharoen; Christophe Prehaud; Craig J van Dolleweerd; Leonard Both; Anaelle da Costa; Monique Lafon; Julian K-C Ma
Journal:  Plant Biotechnol J       Date:  2017-04-19       Impact factor: 9.803

3.  Platelets transport β-amyloid from the peripheral blood into the brain by destroying the blood-brain barrier to accelerate the process of Alzheimer's disease in mouse models.

Authors:  Tong Wu; Lizhi Chen; Lingqi Zhou; Jie Xu; Kaihua Guo
Journal:  Aging (Albany NY)       Date:  2021-03-05       Impact factor: 5.682

Review 4.  Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment.

Authors:  Analiz Rodriguez; Stephen B Tatter; Waldemar Debinski
Journal:  Pharmaceutics       Date:  2015-08-03       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.